Ptc Therapeutics (PTCT) Payables (2012 - 2026)

Ptc Therapeutics' Payables history runs 15 years deep, the most recent figure standing at $382.2 million for Q2 2026.

• In Q2 2026, Payables rose 12.77% year-over-year to $382.2 million; the TTM figure through Jun 2026 stood at $382.2 million (up 12.77% YoY), while the FY2025 annual figure was $381.3 million, up 25.3% from the prior year.
• Payables for Q2 2026 stood at $382.2 million, up from $313.0 million in the prior quarter.
• The five-year high for Payables was $392.0 million in Q4 2023, with the low at $246.5 million in Q1 2022.
• The 5-year median for Payables is $331.5 million (2023), against an average of $334.9 million.
• The sharpest annual moves came in 2022 and 2024: Payables surged 40.27% in 2022, then declined 22.37% in 2024.
• Ptc Therapeutics' Payables stood at $320.4 million in 2022, then climbed by 22.35% to $392.0 million in 2023, then declined by 22.37% to $304.3 million in 2024, then gained by 25.3% to $381.3 million in 2025, then increased by 0.26% to $382.2 million in 2026.
• Business Quant data shows PTCT's Payables at $382.2 million in Q2 2026, $313.0 million in Q1 2026, and $381.3 million in Q4 2025.